Search the Newsreel

Galectin Therapeutics Q2 Results: EPS misses estimate, losses widen

Galectin Therapeutics Releases Q2 2026 Financial Results

Galectin Therapeutics Inc. (GALT) reported a wider net loss of $0.14 per share, or $9.1 million, for Q2 2026, an increase from $0.12 per share in the prior year. This reflects the company's continued investment in developing new drugs for fibrotic disease and cancer …

Is Galectin Therapeutics Inc (GALT) Overvalued After Q2 Earnings Miss? GF Score: 22/100

Galectin Therapeutics reports Q2 2026 net loss $9.2M, cash $13.3M, submits Phase 3 protocol

Galectin Therapeutics reported a Q2 2026 net loss of $9.2 million and held $13.3 million in cash. The company plans to submit a registrational Phase 3 protocol for belapectin in advanced MASH cirrhosis in Q3 2026, having aligned with the FDA on key trial …

Galectin Reports $9.1 Million Q2 Net Loss and FDA Phase 3 Agreement

Galectin Therapeutics (GALT) announced a net loss of $9.1 million for Q2 2026, or $0.14 per share, an increase from $7.6 million in the prior-year quarter. The company also reached an agreement with the FDA on key elements for its planned Phase 3 belapectin …

Galectin Therapeutics (NASDAQ:GALT) Upgraded to Hold at Zacks Research

Zacks Research upgraded Galectin Therapeutics (NASDAQ:GALT) from a "strong sell" to a "hold" rating. The company received a consensus "Hold" rating and an $11.00 target price from various analysts. Galectin Therapeutics' stock opened at $3.14, with a market capitalization of $206.8 million, and the …

Galectin Therapeutics Inc expected to post a loss of 9 cents a share - Earnings Preview

Galectin Therapeutics Inc is anticipated to report a loss of 9 cents per share. This information is presented as an earnings preview by Reuters, accessible through TradingView News.

Galenica Ltd (WBO:GALE) (H1 2026) Earnings Call Highlights: Strong Core Growth and Strategic ...

This article first appeared on GuruFocus. Release Date: August 06, 2026 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Galenica Ltd (WBO:GALE) achieved strong sales growth of 7.1% to CHF2.136 billion and increased adjusted …

Galenica AG bestätigt Ergebnisprognose für das Jahr 2026

Galectin Therapeutics strengthens balance sheet via debt-to-equity conversion

Galectin Therapeutics (GALT) converted $105.8 million in debt and accrued interest from its chairman and major shareholder, Richard E. Uihlein, into equity by issuing 34,376,167 common shares. This transaction significantly improved the company's balance sheet, increased Uihlein's voting power, and provides financial flexibility for …

Galectin Therapeutics (GALT) Projected to Announce Quarterly Earnings on Thursday

Richard Uihlein converts GALT debt into 34,376,167 new shares

Richard E. Uihlein has converted approximately $105.8 million in debt owed by Galectin Therapeutics Inc. (GALT) into 34,376,167 shares of common stock. This transaction increases his beneficial ownership to 54,673,646 shares, representing about 49.30% of the outstanding common stock. Uihlein maintains sole voting and …

Galectin Therapeutics (GALT) director converts credit notes into stock

Richard E. Uihlein, a director and over-10% holder of Galectin Therapeutics (GALT), converted Line of Credit Convertible Notes totaling over $100 million into 34,376,167 common shares at prices of $3.00 and $4.05 per share. This transaction significantly increased his indirect common stock holdings via …

Galectin Therapeutics Announces Conversion of $105.8 Million in Debt to Equity, Significantly Strengthening Balance Sheet

Galectin Therapeutics announced that its Chairman, Richard E. Uihlein, converted $105.8 million in outstanding debt, including principal and accrued interest, into 34,376,167 shares of common stock. This conversion significantly strengthens the company's balance sheet by eliminating substantial debt and reflects Mr. Uihlein's continued confidence …

Galectin Therapeutics (NASDAQ:GALT) Share Price Passes Above Two Hundred Day Moving Average - Here's Why

Galectin Therapeutics Inc (GALT) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Galectin Therapeutics Inc (GALT), detailing its support, resistance levels, and various technical indicators. It presents a summary of buy, sell, and neutral signals from indicators like MACD, RSI, and moving averages, concluding with a neutral overall signal …

Galectin Therapeutics Inc. Revenue Breakdown – NASDAQ:GALT

This page provides financial overview information for Galectin Therapeutics Inc. (NASDAQ: GALT). It details access to financial statements, statistics, dividends, earnings, and segment performance. The page is part of TradingView, which offers various market analysis tools and data.

Gale Pacific Ltd (ASX:GAP) Worth Watching on Positive Sentiment

Galectin Therapeutics Inc (GALT) Financial Health: Profitability & Balance Sheet Analysis

This article provides a brief overview of Galectin Therapeutics Inc (GALT)'s financial health, focusing on profitability and balance sheet analysis. It presents current stock price, market capitalization, and a prompt for more detailed financial and analysis information. The content also notes the absence of …

Galectin Therapeutics Inc (GALT) Cash Flow

This article provides a detailed cash flow statement for Galectin Therapeutics Inc (GALT), categorizing quarterly financial data into operating, investing, and financing cash flows from FY2012Q1 to FY2026Q1. It includes a market overview with current stock price, market cap, and P/E, alongside FAQs explaining …

TradingKey

This article provides a detailed balance sheet analysis for Galectin Therapeutics Inc (GALT), displaying quarterly and annual data for various assets, liabilities, and shareholder equity components. It highlights key financial figures such as total assets, current assets, non-current assets, total liabilities, and total shareholders' …

GALT|Galectin Therapeutics Inc|Price:3.390|Chg%:-0.080

This article from TradingKey provides an overview and analysis of Galectin Therapeutics Inc (GALT). It details the methodology behind TradingKey's comprehensive Stock Score, which assesses companies based on 34 indicators across six dimensions, including financial health, earnings forecasts, and institutional confidence. However, it notes …

GALT stock reacts to Galectin Therapeutics Q1 2026 cash position and R&D progress

Galectin Therapeutics Inc. (GALT) reported its Q1 2026 financials, showing a cash position of $25.4 million, down from $32.7 million in Q4 2025 due to increased research and development (R&D) spending. The company's net loss widened to $8.1 million as R&D expenses rose by …

Galectin Therapeutics (NASDAQ:GALT) Stock Passes Above 200-Day Moving Average - Here's Why

GALT stock gains support as Galectin Therapeutics keeps cash focus

Galectin Therapeutics (GALT) is being evaluated based on its cash reserves, R&D expenses, and clinical trial progress for its lead program, belapectin, rather than revenue. The company reported $21.5 million in cash and cash equivalents and $5.9 million in R&D expenses for Q1 2026, …

Form 4 Galectin Therapeutics Inc For: 16 July By Investing.com

This article reports on the Form 4 filing for Galectin Therapeutics Inc., which was published on July 16, 2026. Form 4s disclose changes in beneficial ownership of securities by company insiders. The article uses a standard format provided by Investing.com for regulatory filings but …

Galectin Therapeutics CMO Jamil Khurram sells $83,284 in stock

Jamil Khurram, Chief Medical Officer of Galectin Therapeutics Inc., sold 16,250 shares of common stock for $83,284 on July 14, 2026, under a Rule 10b5-1 trading plan. This sale occurred after he exercised stock options for the same number of shares at a lower …

Galectin Therapeutics (GALT) CMO sells 16,250 shares under 10b5-1 plan

Galectin Therapeutics Chief Medical Officer Jamil Khurram exercised stock options to acquire 16,250 common shares at $3.04 each and subsequently sold all 16,250 shares at a weighted average price of $5.1252 on July 14, 2026. This transaction was conducted under a Rule 10b5-1 trading …

GALT Forecast — Price Target — Prediction for 2027

Galectin Therapeutics (GALT) Announces FDA Agreement for Phase 3 Program

Galectin Therapeutics Announces Positive Type C Meeting with the FDA for Belapectin in Patients with MASH Cirrhosis and Portal Hypertension

GALT Q1 2026 Earnings: Clinical-Stage Biotech Reports Wider-Than-Expected Loss as Stock Edges Higher - Net Profit Margin

Galectin Therapeutics (GALT) Slips 1.87% as Shares Consolidate Near Key Support - Revenue Growth Stocks